Navigation Links
UCI receives $5M from Edwards Lifesciences
Date:9/12/2007

Irvine, Calif., September 12, 2007 - UC Irvines Henry Samueli School of Engineering has received a $5 million gift from Edwards Lifesciences Corporation to establish a center focused on researching and developing the next generation of cardiovascular devices.

The Edwards Lifesciences Center for Advanced Cardiovascular Technology will promote interaction and collaboration among students, faculty members and experts by incorporating both undergraduate and graduate programs related to heart and vascular diseases. The programs will be directed by UCIs Department of Biomedical Engineering, and will involve a variety of other disciplines, including students from the Integrated Nanosystems Research Facility, the California Institute for Telecommunications and Information Technology, the Donald Bren School of Information and Computer Sciences, the Beckman Laser Institute, and UCIs Schools of Medicine, Physical Sciences, and Biological Sciences.

The center also will provide a training environment for hosting prominent experts in the field of cardiovascular technology. It will be located in Engineering 3, a new building on the UCI campus scheduled for completion in August 2009.

A national search is under way for a director, who will be charged with establishing a strategic plan and forming a leadership council to determine the centers specific direction.

Our goal is to create an interdisciplinary facility that encourages students, faculty, researchers and visiting scholars to collaborate and exchange new ideas to drive the development of cardiovascular advancements and devices, said Steven C. George, M.D., William J. Link chair and professor of the Department of Biomedical Engineering, who is spearheading the centers development. The Edwards Lifesciences Center will thoroughly examine the integration of numerous disciplines, such as materials science, computer science, advanced imaging and microfabrication, or the manufacturing of devices with precision at levels much smaller than a millimeter, which all have the potential to lead to implantable devices that can help treat cardiovascular disease.

The Department of Biomedical Engineering, which was established in 2002 and is comprised of 16 faculty members, focuses on education, training, research and technology in areas like manufacturing miniature devices, biomedical lasers, developing computer simulations, and designing artificial tissues in the area of tissue engineering to further advance biomedical technology.

We are pleased to closely collaborate with Edwards Lifesciences, an international leader in cardiovascular technology, to develop a center that combines exceptional faculty, resources and tools to advance this evolving field, said Nicolaos G. Alexopoulos, dean of The Henry Samueli School of Engineering. UC Irvine is located in one of the largest medical device company clusters in the world, which I believe uniquely positions us to address this critical health care area and initiate a world class center.

Irvine-based Edwards Lifesciences, which develops products and technologies to treat advanced cardiovascular disease, is granting the multiyear gift through the Edwards Lifesciences Fund. The fund was established to support advancements in knowledge and improvements in quality of life to help those affected by cardiovascular disease, particularly in the communities where the companys employees live and work.

We are proud to partner with a neighbor that is as accomplished and committed to excellence as UC Irvine to establish a center devoted to transformational cardiovascular technology research, said Michael A. Mussallem, Edwards Lifesciences' chairman and CEO. This grant is a testament to our dedication to providing innovative solutions for people fighting cardiovascular disease, as well as our commitment to strengthening the communities in which we live and work.


'/>"/>

Contact: Jason Mednick
jmednick@uci.edu
949-824-5951
University of California - Irvine
Source:Eurekalert

Related biology news :

1. DuPonts first biologically derived polymer receives global recognition
2. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
3. Research on antibiotics receives historical recognition
4. Anthrax test, developed by army and CDC, receives FDA approval
5. Research team receives $7.5 million to study cassava
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... 2016  higi SH llc (higi) announced today ... national brands, industry thought-leaders and celebrity influencers looking ... for taking steps to live healthier, more active ... higi has built the largest self-screening health station ... people who have conducted over 185 million biometric ...
(Date:11/24/2016)... 2016 Cercacor today introduced Ember TM ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, ... Rate in approximately 30 seconds. Smaller than a smartphone, ... access to key data about their bodies to help ... Hemoglobin carries oxygen to muscles. When ...
(Date:11/17/2016)... Global Market Watch: Primarily supported by ownership types; ... Academics) market is to witness a value of US$37.1 billion ... Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen from ... 2014-2020. North America is not way ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... Atlanta, Georgia (PRWEB) , ... December 05, 2016 ... ... hydrophobic, lignin-coated nanocellulose, including both cellulose nanocrystals and cellulose nanofibrils. The composition ... nanocellulose. There are also claims directed to combination with polymers, carbon fibers, ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
(Date:12/5/2016)... , December 5, 2016 The ... with almost $108 billion of revenue and some $890 ... were spent on global biopharmaceuticals, and this figure is ... Stock-Callers.com has lined up these four equities for assessment: ... Pharmaceuticals Inc. (NASDAQ: ACAD ), Acorda Therapeutics ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... MA to soon resume cervical and lumbar disc production, company President, Jake Lubinski ... surgeons who are implanting the AxioMed disc in Bern, Lucerne, and Zurich to ...
Breaking Biology Technology: